PHASE 4 DELIVERABLE
Complete MoA / MeA Pharmacology Profiling Package
AMX-B01 — Geniposide-Enriched Purified Botanical API
Document Code: SCF-AMMONEX-HE-AMXB01-P4-0001
Trigger Executed: PROFILE API
Development Stage: Pharmacology Profiling & Mechanistic Validation
Objective:
Establish the mechanistic pharmacology framework for AMX-B01, define hypothesized target engagement pathways, validate SCF role assignments, construct the translational biomarker architecture, and generate the preclinical efficacy hypothesis package for advancement into efficacy studies.
1.0 EXECUTIVE PHARMACOLOGY SUMMARY
Development Candidate
AMX-B01
Active Marker
Geniposide
Therapeutic Classification
SCF-HM-02
(Hepatoenteric Nitrogen Homeostasis Modulator)
Primary Therapeutic Objective
Restore ammonia homeostasis through coordinated modulation of:
- Hepatic nitrogen metabolism
- Gut-liver inflammatory signaling
- Barrier integrity
- Neuroimmune activation
2.0 COMPLETE MODE OF ACTION (MoA)
Functional MoA
AMX-B01 is hypothesized to function through restoration of the Gut–Liver–Brain Nitrogen Homeostasis Axis.
Functional Sequence
Hepatic Dysfunction
↓
Ammonia Accumulation
↓
Neuroimmune Activation
↓
Cognitive Dysfunction
↓
AMX-B01 Intervention
↓
Improved Nitrogen Handling
↓
Reduced Neuroinflammatory Amplification
↓
Improved Functional Homeostasis
SCF MoA Layer Mapping
Layer | Functional Outcome |
Gut | Reduced inflammatory signaling |
Liver | Improved nitrogen metabolism |
Blood | Reduced ammonia burden |
Brain | Reduced neuroimmune activation |
Systemic | Improved metabolic resilience |
3.0 COMPLETE MECHANISM OF ACTION (MeA)
Primary MeA Cluster
MeA-1
Hepatic Nitrogen Metabolism Modulation
Target Systems
- Urea-cycle regulatory pathways
- Nitrogen disposal pathways
- Hepatocyte metabolic signaling
Expected Outcome
Improved ammonia detoxification capacity.
MeA-2
Inflammatory Signal Attenuation
Target Systems
- NF-κB signaling
- Cytokine amplification pathways
Expected Outcome
Reduced inflammatory burden.
MeA-3
Gut–Liver Axis Stabilization
Target Systems
- Intestinal inflammatory signaling
- Barrier-associated pathways
Expected Outcome
Reduced portal inflammatory load.
MeA-4
Neuroimmune Modulation
Target Systems
- Microglial activation pathways
- Cytokine-mediated neuroinflammation
Expected Outcome
Reduction of secondary neurotoxicity.
4.0 TARGET ENGAGEMENT MATRIX
Primary Target Tier
Target System | Functional Purpose | Priority |
Nitrogen metabolism pathways | Ammonia handling | Critical |
Hepatic metabolic signaling | Detoxification support | Critical |
NF-κB pathway | Inflammation control | High |
TNF-α signaling | Neuroimmune control | High |
IL-6 signaling | Neuroimmune control | High |
Secondary Target Tier
Target System | Functional Purpose |
Oxidative stress pathways | Hepatic resilience |
Mitochondrial signaling | Energy preservation |
Barrier integrity pathways | Gut-liver stabilization |
NLRP3-associated signaling | Neuroimmune amplification |
5.0 SCF ROLE ASSIGNMENT VALIDATION
Primary Role
Metabolic Regulator
Evidence Basis:
- Hepatic disease alignment
- Nitrogen metabolism focus
- Hepatocyte-centric activity hypothesis
Status:
Validated for preclinical investigation.
Secondary Role
Target Modulator
Evidence Basis:
- Multi-node pathophysiology alignment
Status:
Validated.
Tertiary Role
Safety Harmonizer
Evidence Basis:
- Botanical source history
- Anti-inflammatory mechanistic profile
Status:
Requires experimental confirmation.
6.0 PHARMACOLOGICAL TARGET HIERARCHY
Tier 1 Targets
Highest Priority
- Nitrogen metabolism pathways
- Hepatic metabolic regulators
- NF-κB
- TNF-α
- IL-6
Tier 2 Targets
- NLRP3-associated signaling
- Oxidative stress pathways
- Mitochondrial stress pathways
- Gut barrier pathways
7.0 BIOMARKER ARCHITECTURE
Primary Pharmacodynamic Biomarkers
Biomarker | Purpose |
Plasma ammonia | Primary efficacy marker |
Urea | Nitrogen metabolism |
Citrulline | Urea-cycle function |
Ornithine | Nitrogen handling |
Glutamine | Neurotoxicity marker |
Secondary Biomarkers
Biomarker | Purpose |
IL-6 | Inflammatory response |
TNF-α | Neuroimmune activation |
CRP | Systemic inflammation |
LPS | Gut barrier dysfunction |
Exploratory Biomarkers
Biomarker | Purpose |
EEG | Neural function |
Neurofilament light chain | Neural injury |
Cognitive testing | Translational relevance |
8.0 TRANSLATIONAL PHARMACOLOGY PACKAGE
Cell-Based Program
Hepatocyte Studies
Endpoints:
- Urea production
- Ammonia disposal
- Mitochondrial function
Gut Barrier Studies
Endpoints:
- TEER
- Zonulin
- Claudin-1
- Occludin
Neuroimmune Studies
Endpoints:
- TNF-α
- IL-6
- NLRP3-associated markers
Organoid Program
Liver Organoids
Evaluate:
- Nitrogen metabolism
- Hepatocyte resilience
Gut Organoids
Evaluate:
- Barrier integrity
- Inflammatory signaling
9.0 PRECLINICAL EFFICACY HYPOTHESES
Hypothesis 1
AMX-B01 will reduce circulating ammonia in hyperammonemia models.
Success Endpoint
≥30% reduction versus control.
Hypothesis 2
AMX-B01 will improve hepatic nitrogen metabolism.
Success Endpoint
Improved urea-cycle biomarker profile.
Hypothesis 3
AMX-B01 will reduce neuroinflammatory signaling.
Success Endpoint
Reduction in TNF-α and IL-6.
Hypothesis 4
AMX-B01 will improve neurobehavioral outcomes.
Success Endpoint
Improved cognition and neurological scores in HE models.
10.0 SCF SYNERGY REASSESSMENT
Updated Mechanistic Scores
Metric | Predicted Score |
TSSM | 9.0 |
HSV-F² | 8.9 |
SV-EQ | 9.1 |
MGIS | 8.8 |
SPCI | 9.2 |
Composite Pharmacology Score
90.0 / 100
These scores are internal SCF research metrics and not validated regulatory measures.
11.0 DEVELOPMENT RISKS
Risk | Category | Priority |
Weak ammonia reduction | Efficacy | High |
Limited oral exposure | PK | High |
Variable botanical composition | CMC | Moderate |
Insufficient target engagement | Pharmacology | Moderate |
Unexpected hepatotoxicity | Safety | Moderate |
12.0 PHASE 4 DECISION GATE
Advancement Criteria
✓ Mechanistic hypothesis established
✓ Biomarker architecture defined
✓ Translational pharmacology framework completed
✓ Target engagement matrix established
✓ SCF role assignment validated
✓ Preclinical efficacy hypotheses defined
Status
ADVANCE TO PHASE 5
Required Next Trigger
PK BUILD
Phase 5 will generate:
- ADME development package
- Absorption optimization strategy
- Distribution and tissue-targeting model
- Metabolism characterization plan
- Excretion strategy
- Formulation engineering package
- PK/PD modeling framework
- Development-candidate exposure targets
MASTER REGISTRY INDEX
SCF-AMMONEX-HE-AMXB01-P4-0001 — Pharmacology Profiling Package
SCF-AMMONEX-HE-AMXB01-MOA-0002 — Mode of Action Framework
SCF-AMMONEX-HE-AMXB01-MEA-0003 — Mechanism of Action Framework
SCF-AMMONEX-HE-AMXB01-BIO-0004 — Biomarker Architecture
SCF-AMMONEX-HE-AMXB01-TPX-0005 — Translational Pharmacology Package
SCF-AMMONEX-HE-AMXB01-EFF-0006 — Preclinical Efficacy Hypotheses
SCF-AMMONEX-HE-AMXB01-P5-0007 — PK Engineering Program Initiation